Loading…

Neurones SANRO.PACompetitor analysis, valuation and peers

France · EUR·Industrials›Miscellaneous Commercial Services

French IT services company providing infrastructure management, consulting and outsourcing to mid-size and large enterprises.

≈ A smaller French IT-services firm like a mini Sopra SteriaMomentum strong 78
Mkt cap
$1.03B
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$357,943
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
+18.0 pp
WACC 7.5%
Hurdle
-18 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · EUR€39.40
1D-0.8%
1W-2.8%
1M+7.7%
3M+3.3%
6M+3.3%
YTD-8.5%
1Y-7.2%
ATR %2.6%
52w lowhigh12.4% off high

What Neurones does

French IT services company providing infrastructure management, consulting and outsourcing to mid-size and large enterprises.

Sells staff time and managed services: infrastructure outsourcing contracts bill for running a client's systems over several years, while consulting and software-engineering work is billed by the day. Growth has come partly from buying small firms and keeping them as semi-independent subsidiaries.

In one line: A smaller French IT-services firm like a mini Sopra Steria.

Products and services

  • IT infrastructure management/outsourcing
  • Consulting
  • Application/software engineering

Customers

  • Mid-market & large French enterprises
  • Public sector

Where it sits in the supply chain

  • Information technology
  • IT services
  • Infrastructure management & consulting

What could go right

  • SME digitalization demand

What could go wrong

  • Price competition from larger IT-services players

Moat: none (installed base). Solid regional IT-services relationships but no structural advantage over larger, better-resourced peers.

Headquarters: Levallois-Perret, France · Founded: 1985 · Employees: 7,208

Named competitors

Neurones at a glance

Size Neurones (NRO.PA) is a France Industrials company (Miscellaneous Commercial Services) with a market value of $1.03B, the 137th largest of 206 France companies the cockpit tracks. Shares closed at €39.40 on 18 Nov 2026.

Performance Over six months the shares gained 3.3%, against -13.9% for the median peer and -2.1% for the France market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 6.7% over the last twelve months (peer median +6.9%); the operating margin is 8.9% (peer median 10.4%).

Valuation It trades at 16.9× forward earnings against a peer median of 16.7× (9th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.0 points above its cost of capital (7.5% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026NRO.PA 105Peer median 88
Six months, rebased to 100: Neurones against the median of its 20 peers (local-currency closes).

Neurones financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€888M€857M€810M€741M€665M
Revenue growth—+6%+9%+11%—
Gross profit€97.5M€90.0M€89.3M€86.4M€81.6M
EBITDA€96.3M€90.3M€93.3M€89.0M€86.3M
Net income€55.2M€52.1M€52.6M€49.4M€44.2M
Free cash flow€88.6M€70.3M€82.5M€59.0M€44.3M
Capital expenditure€12.2M€10.4M€12.0M€18.0M€10.6M
Total debtn/a€37.0M€42.0M€44.0M€35.6M

Quarterly statements and history in the cockpit →

Neurones competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%131970SSM688522BMAG688392300938CASHSIQGLO605098RITES603123GNC0667600861300795301189688137WLDNNRO.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Neurones is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%20×40×131970SSM688522BMAG688392300938CASHSIQGLO605098RITESGNC0667600861300795600645NRO.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Neurones is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%SSMCASHSIQGLO605098RITES0667600645WLDNNRO.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Neurones is the large dot.

Neurones competitors and peer comparison

Head to head with its named competitors (NRO.PA vs SOP.PA vs ATO.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Neurones NRO.PA$1.03B+3%+7%9%16.9×-7.9%
Sopra Steria SOP.PA$3.93B+32%+2%9%10.6×-1.4%
Atos ATO.PA$482M-49%-14%6%n/an/a

How Neurones compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neurones against its 20 peers (data as of 18 Nov 2026)
MeasureNRO.PAPeer medianRank in peer set
1-month return+7.7%-7.9%2nd highest of 21
6-month return+3.3%-13.9%6th highest of 21
Distance from 52-week high-12.4%-36.7%2nd highest of 21
Revenue growth (TTM)+6.7%+6.9%11th highest of 21
Operating margin8.9%10.4%9th lowest of 21
Forward P/E16.9×16.7×9th most expensive of 18
Growth the price implies (Req g, 7 yrs)-7.9%3.4%2nd least demanding of 10
Growth delivered (Del g)+10.3%+8.8%5th highest of 10
Hurdle (Req g minus delivered)-18.3 pp-10.0 pp3rd least demanding of 10
ROIC minus cost of capital+18.0 pp-0.5 pp2nd highest of 19
EV / EBITDA7.6×8.7×4th cheapest of 9
Net debt / EBITDA-2.7×0.5×2nd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neurones NRO.PAFrance$1.03B+3%+7%9%16.9×-7.9%+10.3%
DOOSAN TESNA 131970.KSSouth Korea$1.03B-62%+5%10%43.1×n/an/a
Service Stream SSM.AXAustralia$1.03B-9%+1%3%16.7×13.9%+24.0%
Naruida Technology 688522.SSChina$1.01B-32%+20%14%19.6×n/an/a
Bajaj Mobility BMAG.SWSwitzerland$1.05B+40%-47%-44%8.9×n/an/a
SBT Ultrasonic Technology 688392.SSChina$1.06B-36%+42%17%49.3×n/an/a
EMTEK (Shenzhen) 300938.SZChina$1,000M-54%+11%27%28.5×n/an/a
Prosegur Cash CASH.MCSpain$1.07B+10%-2%11%9.6×-12.1%+5.7%
Smartgroup SIQ.AXAustralia$986M-6%+10%37%14.7×-1.3%+8.8%
GL events GLO.PAFrance$986M-13%+6%10%8.8×3.4%+29.1%
Shanghai Action Education Tehnology 605098.SSChina$981M-10%+15%40%16.1×-3.1%+16.4%
Rites RITES.NSIndia$979M-7%+11%19%20.9×19.6%+5.3%
Beijing Cuiwei Tower 603123.SSChina$978M-26%-12%-18%n/an/an/a
Graincorp GNC.AXAustralia$976M+41%-2%-1%21.9×n/an/a
China East Education 0667.HKHong Kong$1.09B-21%+16%22%7.8×-7.5%+4.1%
FESCO 600861.SSChina$1.10B-15%+4%1%10.5×n/an/a
Zhejiang Meorient Commerce & Exhibition 300795.SZChina$962M+16%-3%18%39.6×n/an/a
Vcanbio Cell & Gene Engineering 600645.SSChina$1.11B-29%-6%12%40.7×8.9%+1.9%
Shenzhen Aoni Electronic 301189.SZChina$949M-45%+139%2%n/an/an/a
Suzhou Novoprotein Scientific 688137.SSChina$1.12B+117%+8%-62%n/an/an/a
Willdan WLDNUnited States$1.13B-20%+19%7%14.6×17.2%+11.8%

Questions

Who are Neurones's main competitors?
Named competitors: Sopra Steria (SOP.PA), Atos (ATO.PA), Econocom (private or unlisted). The cockpit's measured peer set (industry) also includes DOOSAN TESNA (131970.KS), Service Stream (SSM.AX), Naruida Technology (688522.SS), Bajaj Mobility (BMAG.SW), SBT Ultrasonic Technology (688392.SS), EMTEK (Shenzhen) (300938.SZ).
Is Neurones expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 16.7×, 9th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Neurones stock performed?
Over six months to 18 Nov 2026 the shares returned +3.3% against -13.9% for the median peer; over one year -7.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.